Subject: : Cross sectional survey to gather insights on the perception & clinical usage of high-intensity statins in ACS management among Indian physicians
Cardiovascular disease is the leading cause of death with India accounting for the highest burden of acute coronary syndromes (ACS) in the world. ACS presents a major public health issue with data suggesting that IHD has led to 1.54 million deaths.
A variety of multi-site and regional registries have reported that Indians account for a higher rate of ST-elevation myocardial infarction (STEMI) - 69%; than N-STEMI (31%). Men tend to have a higher incidence of ACS with the mean age of these patients being 58 (±12.5 years). One of the major challenges for management of ACS include presence of modifiable risk factors that predisposes a patient to ACS like - hypertension, diabetes mellitus, dyslipidemia, obesity, smoking, and a sedentary lifestyle. In addition to this, aspects like median time from symptoms to hospital, access to appropriate reperfusion therapy & availability of medical management options could help to reduce morbidity and mortality.
The current ACC/AHA guidelines recommend the use of Nitrates, CCBs, ARBs & high-intensity cholesterol lowering drugs for primary & secondary management of ACS patients. Among all the available medical options, high intensity statin, when initiated early has shown to offer significant reduction of LDL- cholesterol & serum hs-CRP levels in ACS patients. Although, there is literature evidence supporting the use, understanding the importance of choosing an appropriate treatment option considering presence of other comorbidities will help to determine the right approach.
We, at Sun Pharma, always strive to be abreast about the current clinical practices, and perceptions about existing treatment options. With this survey, we intend to understand the treatment landscape about the use of high-intensity statins in ACS management.
The summary/outcome of the same will help us to better understand practice patterns, gap areas and enrich future learning needs, and to improve the care of post-ACS patients. Your responses will be used at an aggregate level.
|
}}){kind=logo}
}})